These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 37657507)

  • 21. Effects of surfaces and leachables on the stability of biopharmaceuticals.
    Bee JS; Randolph TW; Carpenter JF; Bishop SM; Dimitrova MN
    J Pharm Sci; 2011 Oct; 100(10):4158-70. PubMed ID: 21523787
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overview of the nonclinical quality and toxicology testing for recombinant biopharmaceuticals produced in mammalian cells.
    Lebrec H; Narayanan P; Nims R
    J Appl Toxicol; 2010 Jul; 30(5):387-96. PubMed ID: 20589744
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Appropriate mammalian expression systems for biopharmaceuticals.
    Werner RG; Noé W; Kopp K; Schlüter M
    Arzneimittelforschung; 1998 Aug; 48(8):870-80. PubMed ID: 9748718
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Throughput Optimization of Continuous Biopharmaceutical Manufacturing Facilities.
    Garcia FA; Vandiver MW
    PDA J Pharm Sci Technol; 2017; 71(3):189-205. PubMed ID: 27974629
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Formulation strategies and particle engineering technologies for pulmonary delivery of biopharmaceuticals.
    Cun D; Wan F; Yang M
    Curr Pharm Des; 2015; 21(19):2599-610. PubMed ID: 25876915
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Spray Freeze Drying of Biologics: A Review and Applications for Inhalation Delivery.
    Farinha S; Sá JV; Lino PR; Galésio M; Pires J; Rodrigues MÂ; Henriques J
    Pharm Res; 2023 May; 40(5):1115-1140. PubMed ID: 36456666
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Insights on the Formulation of Recombinant Proteins.
    Ribeiro R; Abreu TR; Silva AC; Gonçalves J; Moreira JN
    Adv Biochem Eng Biotechnol; 2020; 171():23-54. PubMed ID: 31844925
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nanomedicines for delivery of therapeutic proteins and biopharmaceuticals.
    Sarmento B
    Ther Deliv; 2010 Aug; 1(2):231-5. PubMed ID: 22816130
    [TBL] [Abstract][Full Text] [Related]  

  • 29. On the verge of the market - Plant factories for the automated and standardized production of biopharmaceuticals.
    Huebbers JW; Buyel JF
    Biotechnol Adv; 2021; 46():107681. PubMed ID: 33326816
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation and Screening of Biopharmaceuticals using Multi-Angle Dynamic Light Scattering.
    Sharma A; Beirne J; Khamar D; Maguire C; Hayden A; Hughes H
    AAPS PharmSciTech; 2023 Mar; 24(4):84. PubMed ID: 36949219
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proteins behaving badly: emerging technologies in profiling biopharmaceutical aggregation.
    Hamrang Z; Rattray NJ; Pluen A
    Trends Biotechnol; 2013 Aug; 31(8):448-58. PubMed ID: 23769716
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Equipment and Analytical Companies Meeting Continuous Challenges May 20-21 2014 Continuous Manufacturing Symposium.
    Page T; Dubina H; Fillipi G; Guidat R; Patnaik S; Poechlauer P; Shering P; Guinn M; Mcdonnell P; Johnston C
    J Pharm Sci; 2015 Mar; 104(3):821-831. PubMed ID: 28756844
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Continuous processing for production of biopharmaceuticals.
    Rathore AS; Agarwal H; Sharma AK; Pathak M; Muthukumar S
    Prep Biochem Biotechnol; 2015; 45(8):836-49. PubMed ID: 25674930
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emerging trends in pulmonary delivery of biopharmaceuticals.
    Kunde SS; Ghosh R; Wairkar S
    Drug Discov Today; 2022 May; 27(5):1474-1482. PubMed ID: 35143963
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aggregates in monoclonal antibody manufacturing processes.
    Vázquez-Rey M; Lang DA
    Biotechnol Bioeng; 2011 Jul; 108(7):1494-508. PubMed ID: 21480193
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Developments and opportunities in continuous biopharmaceutical manufacturing.
    Khanal O; Lenhoff AM
    MAbs; 2021; 13(1):1903664. PubMed ID: 33843449
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hot melt extrusion: An emerging manufacturing method for slow and sustained protein delivery.
    Zheng Y; Pokorski JK
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2021 Sep; 13(5):e1712. PubMed ID: 33691347
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Market of Biopharmaceutical Medicines: A Snapshot of a Diverse Industrial Landscape.
    Moorkens E; Meuwissen N; Huys I; Declerck P; Vulto AG; Simoens S
    Front Pharmacol; 2017; 8():314. PubMed ID: 28642701
    [No Abstract]   [Full Text] [Related]  

  • 39. Next Generation Biopharmaceuticals: Product Development.
    Mathaes R; Mahler HC
    Adv Biochem Eng Biotechnol; 2018; 165():253-276. PubMed ID: 29637223
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Application of a kosmotrope-based solubility assay to multiple protein therapeutic classes indicates broad use as a high-throughput screen for protein therapeutic aggregation propensity.
    Yamniuk AP; Ditto N; Patel M; Dai J; Sejwal P; Stetsko P; Doyle ML
    J Pharm Sci; 2013 Aug; 102(8):2424-39. PubMed ID: 23712759
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.